Seroatlas · Human Serome Atlas

FZD2

Frizzled-2

Also known as: FZD2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q14332
Gene
FZD2
Ensembl
ENSG00000180340
Chromosome
17
Canonical length
565 aa
Protein class
Cancer-related genes, Disease related genes, G-protein coupled receptors, Human disease related genes, Potential drug targets, Predicted membrane proteins
Subcellular location
Nucleoplasm,Nuclear bodies,Cell Junctions,Actin filaments,Basal body

OverviewNCBI Gene

This intronless gene is a member of the frizzled gene family. Members of this family encode seven-transmembrane domain proteins that are receptors for the wingless type MMTV integration site family of signaling proteins. This gene encodes a protein that is coupled to the beta-catenin canonical signaling pathway. Competition between the wingless-type MMTV integration site family, member 3A and wingless-type MMTV integration site family, member 5A gene products for binding of this protein is thought to regulate the beta-catenin-dependent and -independent pathways. [provided by RefSeq, Dec 2010]

Canonical amino-acid sequenceUniProt

565 residues, UniProt reviewed canonical sequence.

>Q14332|FZD2
     1  MRPRSALPRL LLPLLLLPAA GPAQFHGEKG ISIPDHGFCQ PISIPLCTDI AYNQTIMPNL
    61  LGHTNQEDAG LEVHQFYPLV KVQCSPELRF FLCSMYAPVC TVLEQAIPPC RSICERARQG
   121  CEALMNKFGF QWPERLRCEH FPRHGAEQIC VGQNHSEDGA PALLTTAPPP GLQPGAGGTP
   181  GGPGGGGAPP RYATLEHPFH CPRVLKVPSY LSYKFLGERD CAAPCEPARP DGSMFFSQEE
   241  TRFARLWILT WSVLCCASTF FTVTTYLVDM QRFRYPERPI IFLSGCYTMV SVAYIAGFVL
   301  QERVVCNERF SEDGYRTVVQ GTKKEGCTIL FMMLYFFSMA SSIWWVILSL TWFLAAGMKW
   361  GHEAIEANSQ YFHLAAWAVP AVKTITILAM GQIDGDLLSG VCFVGLNSLD PLRGFVLAPL
   421  FVYLFIGTSF LLAGFVSLFR IRTIMKHDGT KTEKLERLMV RIGVFSVLYT VPATIVIACY
   481  FYEQAFREHW ERSWVSQHCK SLAIPCPAHY TPRMSPDFTV YMIKYLMTLI VGITSGFWIW
   541  SGKTLHSWRK FYTRLTNSRH GETTV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FZD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
7
Mean surface accessibility (rSASA)
0.33
Highest tissue expression
9.4 nTPM

Expression across tissuesHPA

Tissue

  • blood vessel: 9.4 nTPM
  • choroid plexus: 8.9 nTPM
  • cervix: 4.6 nTPM
  • endometrium: 3.8 nTPM
  • basal ganglia: 3.4 nTPM
  • placenta: 3.4 nTPM

Single-cell type

  • leydig cells: 45 nCPM
  • peritubular myoid cells: 35 nCPM
  • alveolar cells type 1: 29 nCPM
  • podocytes: 17 nCPM
  • microglia: 14 nCPM
  • monocyte progenitors: 13 nCPM

Immune cell

  • myeloid DC: 1.8 nTPM
  • classical monocyte: 1.1 nTPM
  • plasmacytoid DC: 0.9 nTPM
  • memory CD8 T-cell: 0.2 nTPM
  • total PBMC: 0.2 nTPM
  • intermediate monocyte: 0.1 nTPM

Brain region

  • choroid plexus: 21 nTPM
  • pons: 3.7 nTPM
  • midbrain: 3.5 nTPM
  • white matter: 2.8 nTPM
  • thalamus: 2.6 nTPM
  • basal ganglia: 2.5 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about FZD2.

Disease | AllUniProt

Conditions FZD2 is implicated in, by any mechanism.

Disease | GeneticClinVar

9 pathogenic / likely-pathogenic of 238 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.47
gnomAD pLI
0.65
gnomAD missense Z
3.67
DepMap mean gene effect
-0.07
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FZD2 as an antibody target. Whether an autoantibody or antibody against FZD2 could matter depends on whether native FZD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FZD2 is annotated at the cell surface, where native FZD2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label FZD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/FZD2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...